Nycomed CEO ‘very satisfied’ with third quarter results

Nycomed's chief executive officer Hakan Bjorklund said the company is "very satisfied" with its third quarter financial performance, after experiencing growth in key areas.

According to its latest financial report, the pharmaceutical company saw an 8.7 percent year-on-year growth in net turnover during the quarter, when excluding the impact of a one-time payment made during the three-month period.

It was able to achieve strong growth for a number of key products, while also commencing the European rollout of its chronic obstructive pulmonary disease treatment Daxas.

Mr Bjorklund also highlighted the company's recent expansion in emerging markets via new agreements with firms such as Guangdong Techpool Bio-Pharma and Zydus Cadila.

He added that Nycomed's Q3 2010 performance "demonstrates that our strategy of focusing on emerging markets and specialty products is delivering results".

In September 2010, Nycomed applied for European approval of EX101, a new osteoporosis treatment developed in alliance with EffRx Pharmaceuticals.